Madrigal Pharmaceuticals, Inc. MDGL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s accounts payable?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accounts payable of $60.8M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accounts payable increased by 44.6% year-over-year, from $42.06M to $60.8M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s accounts payable has grown at a 116.9% compound annual growth rate (CAGR), from $1.02M to $48.88M.
- What does accounts payable mean?
- Money the company owes to its suppliers for unpaid bills.
- How do you interpret accounts payable?
- An increase may indicate improved cash flow management through extended payment terms, while a significant spike could signal liquidity constraints.
- How does accounts payable compare across companies?
- Typically benchmarked against industry peers to assess working capital efficiency.